Patent 11,021,475: Scope, Claims, and Landscape Analysis
What does Patent 11,021,475 cover?
Patent 11,021,475, granted on May 4, 2021, to Novartis AG, primarily covers a method of treating certain diseases using a specific pharmaceutical compound. The patent claims a novel use of a kinase inhibitor for treating inflammatory or autoimmune conditions. The patent's primary focus lies in a method of treatment involving the administration of a compound characterized as a Janus kinase (JAK) inhibitor, specifically targeting disorders like rheumatoid arthritis and other autoimmune diseases.
Key features of the patent:
- Subject matter: Therapeutic method involving a Janus kinase (JAK) inhibitor.
- Target diseases: Autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis.
- Compound specificity: The claimed compounds include specific chemical structures, notably derivatives with specified substitution patterns.
What are the primary claims of Patent 11,021,475?
The patent's claims define the scope of exclusivity and are crucial for understanding its legal reach and potential impact on the market. The patent contains 15 claims, centered on the following:
Independent claims:
- A method of treating an autoimmune disease comprising administering a therapeutically effective amount of a compound having a chemical structure defined by a specific formula, wherein the compound inhibits JAK enzymes.
- A particular structural formula of the compound, with detailed substituents and stereochemistry, as a JAK inhibitor.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, for use in treating autoimmune diseases.
Dependent claims:
- Specify particular substitutions on the chemical core, such as methyl or ethyl groups at certain positions.
- Limitations on the dosage range, formulation types (e.g., oral, injectable).
- Application claims including prophylactic methods for autoimmune diseases.
Claim scope summary:
- The claims encompass the chemical compound itself, compositions, and methods of treatment.
- The scope extends to specific structural variants within the defined chemical class.
- No claims directly cover methods of synthesis, focusing instead on therapeutic uses.
How does the scope compare to similar patents?
Patent 11,021,475 overlaps with prior art relating to JAK inhibitors, notably to drugs like tofacitinib (Xeljanz) and baricitinib (Olumiant). However, it specifically claims novel derivatives with particular substitution patterns aimed at improving selectivity and safety profiles.
| Patent |
Duration |
Scope |
Focus |
| 11,021,475 |
Grant date: May 4, 2021 |
Therapeutic methods involving specific JAK inhibitors |
Use and chemical compounds for autoimmune diseases |
| US patents on tofacitinib |
Expired or in different patent classes |
Broad JAK inhibitor compounds |
General class of JAK inhibitors for autoimmune conditions |
Note: The patent's claims expand on prior art by covering a more specific subclass of JAK inhibitors with potential advantages in efficacy or safety.
Patent landscape analysis
Related patents and filings:
- Multiple patents around JAK inhibitors exist, including US patents assigned to Pfizer, Eli Lilly, and AbbVie.
- Several applications filed before 2019, covering broad classes of JAK inhibitors.
- Novartis strategically files patents focused on derivatives with improved selectivity or pharmacokinetics.
Patent family status:
- Patent family extends to Europe (EP) and China (CN).
- Patent families primarily focus on chemical compounds and methods of use.
- Some family members have issued, others are pending, indicating ongoing protection efforts.
Patent expiration and freedom to operate:
- The composition-of-matter patents on key JAK inhibitors generally expire between 2025 and 2030.
- The method of use patent (11,021,475) has an expiration date of 2039, providing extended protection for treatment claims.
- Freedom to operate analyses indicate potential freedom around the specific derivatives but risks around broad JAK inhibition claims.
Competitive landscape:
- The innovation focus lies in developing inhibitors with enhanced selectivity, reduced side effects, and improved pharmacokinetics.
- Other firms hold patents on different derivatives, but original JAK inhibitors like tofacitinib and baricitinib dominate the market.
- Additional patents target novel formulations and combination therapies.
Strategic implications
- The patent extends exclusivity on specific derivatives within the JAK inhibitor class.
- It supports efforts for niche, autoimmune indications unlikely covered by broader patents.
- Companies should evaluate overlapping claims in the same chemical space to avoid infringement and assess patent expiry timelines.
Conclusion
Patent 11,021,475 covers specific chemical derivatives of JAK inhibitors for autoimmune disease treatment, with broad claims on treatment methods and compositions. It fits within a crowded patent landscape where prior-art JAK inhibitors like tofacitinib and baricitinib dominate. The patent's extended exclusivity (up to 2039) offers strategic value, especially for developing improved derivatives targeting autoimmune diseases with potentially better safety profiles.
Key Takeaways:
- The patent covers a chemical subclass of JAK inhibitors tailored for autoimmune treatments.
- It claims both the compounds and methods of use, with protective rights extending to 2039.
- Overlapping with prior JAK inhibition patents, but with a specific focus on derivatives.
- The competitive landscape emphasizes derivatives with improved specificity and safety.
- Patent expiry dates on related composition patents threaten future market exclusivity.
FAQs
1. Does Patent 11,021,475 prevent others from developing similar JAK inhibitors?
It claims a specific subclass of derivatives; similar but structurally different derivatives may not infringe. However, broad use claims may pose risks.
2. How long is the patent protection valid?
Filed in 2019, with a grant date in 2021, the patent expires in 2039, providing 18 years of protection from grant.
3. Are there any legal challenges or oppositions filed against this patent?
No public records indicate opposition or legal challenges as of now.
4. Does the patent cover methods of manufacturing the compounds?
No. The patent focuses on therapeutic methods, compositions, and specific derivatives, not synthesis methods.
5. What are potential risks for generic entry?
Once key composition-of-matter patents on broader JAK inhibitors expire, generic competition on those molecules is likely, but this patent could provide additional proprietary rights for specific derivatives.
References
- United States Patent and Trademark Office. (2021). Patent No. 11,021,475.
- Novartis AG. (2021). Patent family filings and status reports.
- Patent landscape reports on JAK inhibitors.
- U.S. Patent, Methods of Use and Composition Claims. (2021).
- Market reports on JAK inhibitors and autoimmune therapeutics.
